ID   Hu456
AC   CVCL_8238
SY   Hu 456; HU 456; HU456
DR   BioSample; SAMN03151943
DR   cancercelllines; CVCL_8238
DR   Cosmic; 925829
DR   Cosmic; 2037947
DR   GEO; GSM136253
DR   GEO; GSM1574544
DR   Wikidata; Q54896699
RX   PubMed=3708594;
RX   PubMed=6546195;
RX   PubMed=6823318;
RX   PubMed=6826254;
RX   PubMed=7262169;
RX   PubMed=8105864;
RX   PubMed=8900435;
RX   PubMed=11416159;
RX   PubMed=20143388;
RX   PubMed=24018021;
RX   PubMed=25997541;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a T24 derivative (PubMed=3708594; PubMed=8105864; PubMed=20143388).
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00129.
CC   Population: Caucasian; Swedish.
CC   Doubling time: 21 hours (PubMed=3708594).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=11416159
ST   Amelogenin: X
ST   D18S51: 16,18
ST   D21S11: 29
ST   D8S1179: 14
ST   FGA: 22
ST   TH01: 6
ST   vWA: 17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 28
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=6546195; DOI=10.1007/BF00121494;
RA   Schroyens W., Mareel M.M., Dragonetti C.;
RT   "In vitro invasiveness of human bladder cancer from cell lines and
RT   biopsy specimens.";
RL   Clin. Exp. Metastasis 1:153-162(1983).
//
RX   PubMed=6823318; DOI=10.1038/301429a0;
RA   O'Toole C.M., Povey S., Hepburn P.J., Franks L.M.;
RT   "Identity of some human bladder cancer cell lines.";
RL   Nature 301:429-430(1983).
//
RX   PubMed=6826254; DOI=10.1002/ijc.2910310308;
RA   Paulie S., Hansson Y., Lundblad M.-L., Perlmann P.;
RT   "Lectins as probes for identification of tumor-associated antigens on
RT   urothelial and colonic carcinoma cell lines.";
RL   Int. J. Cancer 31:297-303(1983).
//
RX   PubMed=7262169; DOI=10.1016/0014-2964(81)90123-7;
RA   Vilien M., Wolf H., Rasmussen F.;
RT   "Immunological characterization of cell lines establishing from
RT   malignant and normal human urothelium.";
RL   Eur. J. Cancer 17:321-327(1981).
//
RX   PubMed=8105864; DOI=10.1038/bjc.1993.449;
RA   Christensen B., Hansen C., Debiec-Rychter M., Kieler J., Ottensen S.,
RA   Schmidt J.;
RT   "Identity of tumorigenic human urothelial cell lines and
RT   'spontaneously' transformed sublines.";
RL   Br. J. Cancer 68:879-884(1993).
//
RX   PubMed=8900435; DOI=10.1002/(SICI)1097-0215(19961009)68:2<239::AID-IJC17>3.0.CO;2-5;
RA   Klopocki A.G., Krop-Watorek A., Dus D., Ugorski M.;
RT   "Adhesion of human uroepithelial cells to E-selectin: possible
RT   involvement of sialosyl LewisA-ganglioside.";
RL   Int. J. Cancer 68:239-244(1996).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//